- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: LDK378 中文名稱:色瑞替尼
Ceritinib是一種有效的ALK抑制劑,在無細胞試驗中IC50為0.2 nM。Ceritinib (LDK378)還可抑制IGF-1R、InsR、STK22D和FLT3對應(yīng)的IC50值分別為8 nM、7 nM、23 nM和60 nM。Phase 3。
Ceritinib Chemical Structure
CAS: 1032900-25-6
規(guī)格 | 價格 | 庫存 | 購買數(shù)量 |
---|---|---|---|
5mg | 1182.86 | 現(xiàn)貨 | |
50mg | 3868.47 | 現(xiàn)貨 | |
200mg | 10720.71 | 現(xiàn)貨 | |
1g | 23900 | 現(xiàn)貨 | |
更大包裝 有超大折扣 | |||
400-668-6834 |
|||
相關(guān)產(chǎn)品 | TAE684 (NVP-TAE684) GSK1838705A Repotrectinib (TPX-0005) AZD3463 AP26113-analog (ALK-IN-1) Ensartinib dihydrochloride ASP3026 | 點擊展開 |
---|---|---|
相關(guān)化合物庫 | 激酶抑制劑庫 酪氨酸激酶抑制劑分子庫 PI3K/Akt 抑制劑庫 細胞周期化合物庫 血管生成相關(guān)化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
KARPAS299 | Apoptosis assay | 60 nM | 24 hrs | Induction of apoptosis in human KARPAS299 cells harboring NPM-ALK at 60 nM after 24 hrs by acridine orange/ethidium bromide staining based fluorescence microscopic method | 29174809 |
SU-DHL1 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
SU-DHL1 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK phosphorylation at Y1278 residue in human SU-DHL1 cells at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
NCI-H3122 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
NCI-H3122 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
SU-DHL1 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
SU-DHL1 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
NCI-H3122 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK phosphorylation at Y1278 residue in human NCI-H3122 cells at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
NCI-H3122 | Function assay | 20 to 200 nM | 1 hr | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis | 29288940 |
SU-DHL1 | Function assay | 30 nM | 16 hrs | Inhibition of ALK autophosphorylation at Y1507 residue in human SU-DHL1 cells at 30 nM after 16 hrs by Western blot analysis | 29627725 |
SU-DHL1 | Function assay | 30 nM | 16 hrs | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 30 nM after 16 hrs by Western blot analysis | 29627725 |
NCI-H3122 | Function assay | 50 to 250 nM | 16 hrs | Induction of ALK degradation in human NCI-H3122 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method | 29660984 |
KARPAS299 | Function assay | 50 to 250 nM | 16 hrs | Induction of ALK degradation in human KARPAS299 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method | 29660984 |
KARPAS299 | Apoptosis assay | 50 nM | 24 hrs | Induction of apoptosis in human KARPAS299 cells assessed as unclear cell shrinkage at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy | 30223120 |
KARPAS299 | Apoptosis assay | 50 nM | 24 hrs | Induction of apoptosis in human KARPAS299 cells assessed as late apoptotic cells at 50 nM after 24 hrs by AO/EB double staining based inverted fluorescence microscopy | 30223120 |
KARPAS299 | Apoptosis assay | 50 nM | 24 hrs | Induction of apoptosis in human KARPAS299 cells assessed as fragmentation at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy | 30223120 |
Ba/F3 NA C1156Y | Growth Inhibition Assay | 72 h | IC50=0.071 μM | 25727400 | |
Ba/F3 NA WT | Growth Inhibition Assay | 72 h | IC50=0.020 μM | 25727400 | |
C1156F/D1203N 2809 | Growth Inhibition Assay | 72 h | IC50=254 ± 99 nM | 25749034 | |
E1210K 748 | Growth Inhibition Assay | 72 h | IC50=187 ± 84 nM | 25749034 | |
N1178H 169 | Growth Inhibition Assay | 72 h | IC50=42 ± 6 nM | 25749034 | |
F1174I 184 | Growth Inhibition Assay | 72 h | IC50=13 ± 0.1 nM | 25749034 | |
I1171T 445 | Growth Inhibition Assay | 72 h | IC50=82 ± 12 nM | 25749034 | |
I1171N 519 | Growth Inhibition Assay | 72 h | IC50=187 ± 87 nM | 25749034 | |
C1156F 1293 | Growth Inhibition Assay | 72 h | IC50=217 ± 115 nM | 25749034 | |
G1128S 1022 | Growth Inhibition Assay | 72 h | IC50=102 ± 38 nM | 25749034 | |
WT 70 | Growth Inhibition Assay | 72 h | IC50=21 ± 8 nM | 25749034 | |
Parental(+IL3) | Growth Inhibition Assay | 72 h | IC50=1586 ± 173 nM | 25749034 | |
Ba/F3 NA L1196M | Growth Inhibition Assay | 72 h | IC50=0.042 μM | 25727400 | |
Ba/F3 NA L1152R | Growth Inhibition Assay | 72 h | IC50=0.288 μM | 25727400 | |
Ba/F3 NA G1202R | Growth Inhibition Assay | 72 h | IC50=0.277 μM | 25727400 | |
Ba/F3 NA G1269A | Growth Inhibition Assay | 72 h | IC50=0.019 μM | 25727400 | |
Ba/F3 NA S1206Y | Growth Inhibition Assay | 72 h | IC50=0.037 μM | 25727400 | |
Ba/F3 EA WT | Growth Inhibition Assay | 72 h | IC50=0.021 μM | 25727400 | |
Ba/F3 EA C1156Y | Growth Inhibition Assay | 72 h | IC50=0.026 μM | 25727400 | |
Ba/F3 EA L1196M | Growth Inhibition Assay | 72 h | IC50=0.019 μM | 25727400 | |
Ba/F3 EA L1152R | Growth Inhibition Assay | 72 h | IC50=0.099 μM | 25727400 | |
Ba/F3 EA G1202R | Growth Inhibition Assay | 72 h | IC50=0.467 μM | 25727400 | |
Ba/F3 EA G1269A | Growth Inhibition Assay | 72 h | IC50=0.033 μM | 25727400 | |
Ba/F3 EA S1206Y | Growth Inhibition Assay | 72 h | IC50=0.038 μM | 25727400 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.0107 μM. | 29288940 | |
NCI-H3122 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.015 μM. | 26568289 | |
NCI-H2228 | Growth inhibition assay | 3 days | Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM. | 29627725 | |
SU-DHL1 | Growth inhibition assay | 3 days | Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM. | 29627725 | |
DFCI114 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human DFCI114 cells expressing EML4-ALK G1269A mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.018 μM. | 26568289 | |
HCC78 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.018 μM. | 27474925 | |
KARPAS299 | Cytotoxicity assay | 2 to 3 days | Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.0228 μM. | 23742252 | |
NCI-H3122 | Function assay | 72 hrs | Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.025 μM. | 27915169 | |
BAF3 | Function assay | 2 to 3 days | Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.026 μM. | 23742252 | |
KARPAS299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM. | 29174809 | |
NCI-H2228 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM. | 30223120 | |
KARPAS299 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.027 μM. | 27474925 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.033 μM. | 26568289 | |
NCI-H3122 | Function assay | 72 hrs | Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM. | 26923695 | |
NCI-H3122 | Function assay | 72 hrs | Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM. | 26923695 | |
NCI-H3122 | Function assay | 72 hrs | Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition after 72 hrs by SRB assay, CC50 = 0.038 μM. | 28385505 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM. | 26568289 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM. | 26568289 | |
KARPAS299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.041 μM. | 30223120 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.0549 μM. | 29288940 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.057 μM. | 26568289 | |
HCC78 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM. | 29174809 | |
HCC78 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM. | 30223120 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.064 μM. | 26568289 | |
DFCI76 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human DFCI76 cells expressing EML4-ALK L1152R mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.072 μM. | 26568289 | |
BA/F3 | Function assay | 72 hrs | Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay, CC50 = 0.075 μM. | 26923695 | |
BA/F3 | Function assay | 72 hrs | Inhibition of EML4 fused ALK L1196M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM. | 27915169 | |
BA/F3 | Function assay | 72 hrs | Inhibition of EML4 fused ALK (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM. | 27915169 | |
BAF3 | Function assay | 72 hrs | Inhibition of ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by WST-1 assay, CC50 = 0.075 μM. | 28385505 | |
KARPAS299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.084 μM. | 29288940 | |
SMS-KCNR | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SMS-KCNR cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.092 μM. | 26568289 | |
NCI-H3122 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay, IC50 = 0.096 μM. | 29288940 | |
NCI-H2228 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.099 μM. | 29174809 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.101 μM. | 26568289 | |
NCI-H2228 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.1026 μM. | 25644671 | |
LAN5 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LAN5 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.122 μM. | 26568289 | |
SU-DHL1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.122 μM. | 29288940 | |
Kelly | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.142 μM. | 26568289 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.164 μM. | 26568289 | |
SH-SY5Y | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.186 μM. | 26568289 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay, IC50 = 0.234 μM. | 29288940 | |
SK-N-SH | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.303 μM. | 26568289 | |
BAF3 | Function assay | 2 to 3 days | Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.3195 μM. | 23742252 | |
SK-N-FI | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.349 μM. | 26568289 | |
CHLA20 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human CHLA20 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.363 μM. | 26568289 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.444 μM. | 26568289 | |
LAN1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LAN1 cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.549 μM. | 26568289 | |
SK-N-BE(2) | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-BE(2) cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.593 μM. | 26568289 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.668 μM. | 26568289 | |
BAF3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.726 μM. | 29288940 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of human EGFR del19/T790M/C797S mutant expressed in mouse Ba/F3 cells assessed as cell growth inhibition after 72 hrs by CellTiter-Glo assay, GI50 = 0.7805 μM. | 29136465 | |
SK-N-AS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 1.045 μM. | 26568289 | |
BAF3 | Cytotoxicity assay | 2 to 3 days | Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 2.477 μM. | 23742252 | |
Ba/F3 | Function assay | 72 hrs | Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 2.747 μM. | 26568289 | |
BA/F3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 5.512 μM. | 26568289 | |
SH-SY5Y | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 29660984 | |
CHLA20 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human CHLA20 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 29660984 | |
SH-SY5Y | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SH-SY5Y cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay | 29660984 | |
CHLA20 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human CHLA20 cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay | 29660984 | |
NCI-H3122 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 29660984 | |
KARPAS299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KARPAS299 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 29660984 | |
SU-DHL1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SU-DHL1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 29660984 | |
KARPAS299 | Cytotoxicity assay | Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.0228 μM. | 23837797 | ||
BA/F3 | Cytotoxicity assay | Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.026 μM. | 23837797 | ||
NCI-H3122 | Antiproliferative assay | Antiproliferative activity against wild type human NCI-H3122 cells, CC50 = 0.038 μM. | 26235945 | ||
BA/F3 | Function assay | Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells, IC50 = 0.0407 μM. | 23837797 | ||
BAF3 | Antiproliferative assay | Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant, CC50 = 0.075 μM. | 26235945 | ||
BA/F3 | Cytotoxicity assay | Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition, IC50 = 0.32 μM. | 23837797 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Ceritinib是一種有效的ALK抑制劑,在無細胞試驗中IC50為0.2 nM。Ceritinib (LDK378)還可抑制IGF-1R、InsR、STK22D和FLT3對應(yīng)的IC50值分別為8 nM、7 nM、23 nM和60 nM。Phase 3。 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
特性 | 不與c-Met交叉反應(yīng),對體內(nèi)葡萄糖穩(wěn)態(tài)比TAE684效果好,有效作用于 Crizotinib復(fù)發(fā)的腫瘤。 | ||||||||||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | LDK378作用于Ba/F3-NPM-ALK和Karpas290細胞,具有顯著的抗增殖活性,IC50分別為26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT細胞,IC50分別為319.5 nM 和 2477 nM。[1] | |||
---|---|---|---|---|
激酶實驗 | 激酶分析 | |||
所有激酶使用桿狀病毒表達技術(shù)表達為組氨酸或GST標(biāo)簽的融合蛋白,除了在大腸桿菌中產(chǎn)生的未標(biāo)記的ERK2。在LabChip遷移實驗中測量激酶活性。實驗在30°C下進行60分鐘。在有或無LDK378存在時,通過線性進展曲線,獲得LDK378對酶活性的作用效果。 | ||||
細胞實驗 | 細胞系 | Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 細胞 | ||
濃度 | ~100 μM | |||
孵育時間 | 2-3 天 | |||
方法 | 表達熒光素酶的細胞與連續(xù)稀釋的LDK378 或 DMSO 溫育2-3天。熒光素酶的表達用來衡量細胞增殖/存活,使用Bright-Glo螢光素酶檢測系統(tǒng)來評估。使用 XLFit軟件獲得 IC50值。 | |||
實驗圖片 | 檢測方法 | 檢測指標(biāo) | 實驗圖片 | PMID |
Western blot | p-ALK / ALK / p-AKT / AKT / p-ERK / ERK pROS1 / ROS1 / pSTAT3 / STAT3 |
![]() |
28425916 | |
Growth inhibition assay | Cell viability |
![]() |
29067644 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | LDK378 用于降低形成反應(yīng)代謝的可能性,在肝微粒體幾乎檢測不到谷胱甘肽(GSH)加合物的水平(<1%)。LDK378具有相對良好的代謝穩(wěn)定性,中度抑制CYP3A4(Midazolam底物)和抑制hERG。LDK378處理動物,與肝臟血流量相比,具有低的血漿清除率(小鼠,大鼠,狗和猴),處理小鼠,大鼠,狗和猴的口服生物利用度都在55%以上。LDK378 處理Karpas299 和H2228 大鼠移植瘤模型,抑制腫瘤生長,誘導(dǎo)腫瘤衰退,這種作用具有劑量依賴性,體重沒有降低。LDK378處理小鼠,劑量高達100 mg/kg,對胰島素水平或血漿葡萄糖的利用無影響。[1] | |
---|---|---|
動物實驗 | Animal Models | 攜帶 Karpas299/H2228腫瘤的 RNU裸鼠 |
Dosages | ~50 mg/kg | |
Administration | 口服飼喂 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT02450903 | Completed | Non-Small-Cell Lung Cancer |
Novartis Pharmaceuticals|Novartis |
August 21 2015 | Phase 2 |
NCT02040870 | Completed | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals|Novartis |
March 7 2014 | Phase 1|Phase 2 |
NCT01950481 | Completed | Normal Hepatic Function|Impaired Hepatic Function |
Novartis Pharmaceuticals|Novartis |
January 2014 | Phase 1 |
NCT01772797 | Completed | Anaplastic Lymphoma Kinase (ALK)|Non-small Cell Lung Cancer |
Novartis Pharmaceuticals|Novartis |
June 2013 | Phase 1 |
NCT01685060 | Completed | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals|Novartis |
November 26 2012 | Phase 2 |
NCT01634763 | Completed | Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) |
Novartis Pharmaceuticals|Novartis |
June 2012 | Phase 1 |
分子量 | 558.14 | 分子式 | C28H36ClN5O3S |
CAS號 | 1032900-25-6 | SDF | Download Ceritinib SDF |
Smiles | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 4 mg/mL ( (7.16 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
how to reconstitute the inhibitor for oral administration to mice?
回答:
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.